Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE)

被引：0
|
作者：
Heo, Jeong
Chao, Yee
Jonker, Derek J.
Baron, Ari David
Habersetzer, Francois
Burke, James
Breitbach, Caroline
Patt, Richard H.
Lencioni, Riccardo
Homerin, Michel
Limacher, Jean-Marc
Lusky, Monika
Hickman, Theresa
Longpre, Lara
Kirn, David H.
机构：
[1] Pusan Natl Univ Hosp, Pusan, South Korea
[2] Taipei Vet Gen Hosp, Taipei, Taiwan
[3] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[4] Calif Pacific Med Ctr, San Francisco, CA USA
[5] Hop Civil, Hop Univ Strasbourg, Strasbourg, France
[6] Jennerex Inc, San Francisco, CA USA
[7] RadMd, Doylestown, PA USA
[8] Pisa Univ Hosp, Div Diagnost Imaging & Intervent, Pisa, Italy
[9] Univ Pisa, Sch Med, I-56100 Pisa, Italy
[10] Transgene SA, Illkirch Graffenstaden, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4161
引用
收藏
页数：1
相关论文
共 18 条
  • [1] Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE)
    Burke, James M.
    Breitbach, Caroline
    Patt, Richard H.
    Lencioni, Riccardo
    Homerin, Michel
    Limacher, Jean-Marc
    Lusky, Monika
    Hickman, Theresa
    Longpre, Lara
    Kirn, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Heo, Jeong
    Breitbach, Caroline
    Cho, Mong
    Hwang, Tae-Ho
    Kim, Chang Won
    Jeon, Ung Bae
    Woo, Hyun Young
    Yoon, Ki Tae
    Lee, Jun Woo
    Burke, James
    Hickman, Theresa
    Longpre, Lara
    Patt, Richard H.
    Kirn, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Phase II trial of pexa-vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC).
    Kim, Seong-Geun
    Ha, Hong Koo
    Lim, Sung-nam
    De Silva, Naomi S.
    Pelusio, Adina
    Mun, Jae Hee
    Patt, Richard H.
    Breitbach, Caroline J.
    Burke, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Phase 2 trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC)
    Kim, S. G.
    Hwang, T. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S510 - S510
  • [5] Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
    Lee, Jeeyun
    Park, Young Suk
    Burke, James
    Lim, Ho Yeong
    Lee, Jihye
    Kang, Won Ki
    Park, Joon Oh
    Pelusio, Adina
    Breitbach, Caroline
    Kirn, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma
    Abou-Alfa, Ghassan K.
    Galle, Peter R.
    Chao, Yee
    Erinjeri, Joseph
    Heo, Jeong
    Borad, Mitesh J.
    Luca, Angelo
    Burke, James
    Pelusio, Adina
    Agathon, Delphine
    Lusky, Monika
    Breitbach, Caroline
    Qin, Shukui
    Gane, Edward
    LIVER CANCER, 2024, 13 (03) : 256 - 272
  • [7] Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
    Moehler, M.
    Heo, J.
    Lee, H. C.
    Tak, W. Y.
    Chao, Y.
    Paik, S. W.
    Yim, H. J.
    Byun, K. S.
    Baron, A.
    Ungerechts, G.
    Jonker, D.
    Ruo, L.
    Cho, M.
    Kaubisch, A.
    Wege, H.
    Merle, P.
    Ebert, O.
    Habersetzer, F.
    Blanc, J. F.
    Rosmorduc, Olivier
    Lencioni, R.
    Patt, R.
    Leen, A. M.
    Foerster, F.
    Homerin, M.
    Stojkowitz, N.
    Lusky, M.
    Limacher, J. M.
    Hennequi, M.
    Gaspar, N.
    McFadden, B.
    De Silva, N.
    Shen, D.
    Pelusio, A.
    Kirn, D. H.
    Breitbach, C. J.
    Burke, J. M.
    ONCOIMMUNOLOGY, 2019, 8 (08):
  • [8] A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
    Toulmonde, M.
    Cousin, S.
    Bessede, A.
    Homerin, M.
    Stojkowitz, N.
    Lusky, M.
    Pulido, M.
    Italiano, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] A phase II trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).
    Heo, Jeong
    Breitbach, Caroline
    Cho, Mong
    Hwang, Tae-Ho
    Kim, Chang Won
    Jeon, Ung Bae
    Woo, Hyun Young
    Yoon, Ki Tae
    Lee, Jun Woo
    Burke, James
    Hickman, Theresa
    DuBois, Kara S.
    Longpre, Lara
    Patt, Richard H.
    Kirn, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study
    Daniele, Bruno
    Di Maio, Massimo
    Gallo, Ciro
    Gasbarrini, Antonio
    Carteni, Giacomo
    Di Costanzo, Giovan Giuseppe
    Craxi, Antonio
    Cabibbo, Giuseppe
    Bolondi, Luigi
    Granito, Alessandro
    Missale, Gabriele
    Frassoldati, Antonio
    Angelico, Mario
    Roselli, Mario
    Daniele, Gennaro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12